TRANS OVA GENETICS

Trans Ova Genetics provides industry-leading reproductive technologies to breeders looking to advance and extend superior genetics.

Trans Ova Genetics understands the process that will help multiply a herd’s genetic success. Reproductive technologies such as embryo transfer, in vitro fertilization, sexed semen, genetic preservation and cloning are considered the reproductive “tools” available for breeders looking to achieve specific breeding and reproductive goals.

Internationally recognized as a source of superior animal husbandry and reproductive expertise, Trans Ova Genetics offers an integrated system of regional centers, satellite centers and on-farm application of reproductive technologies.

From veterinarians and embryologists, to animal caretakers and client service representatives, each location and its team share a consistent commitment to client service that can multiply the results within any breeding program.

Mission Statement

Trans Ova Genetics’ mission is to provide opportunity and advantage through genetic acceleration.

Gregg Topoleski serves as Chief Financial Officer for URUS. With over 23 years in Finance, he has developed a deep operational and strategic skillset that will complement the URUS leadership team. Before joining URUS, most recently, Gregg served as a Finance Executive for Exact Sciences and 3M/KCI. He started his career with GE in the Healthcare and Industrial Technologies divisions.

Petra Vijverberg is Chief Integration Officer of URUS. She brings with her experience as Managing Director Volkswagen and Sr Vice President of Strategy & Business Development of the PON group. At URUS she leads the coordination, alignment, and innovation of People Development & HR, IT, Digital Strategy, Marketing & Global Development, Corporate Development, and Supply Chain & Logistics.

Kevin Muxlow is Chief Operating Officer for URUS. He has a leadership focus on A.I. sales channels, SCCL, and VAS businesses while also building culture and strategy and supporting growth across the URUS Group. Kevin started with the company in 2005 in marketing, people development, and sales leadership roles.

Paul Hunt is the Chief Executive Officer of URUS. He took on this role after serving as the COO of URUS, where he provided leadership and support to GENEX, PEAK, and the URUS aspects of Corporate Development, People Development, and Distribution. Prior to the creation of URUS, Paul was the Alta Genetics COO since 2004. Paul has spent his entire career within URUS and its predecessors.